Chinese Expert Consensus on Immune Checkpoint Inhibitor Therapy for Elderly Patients with Advanced Non-small Cell Lung Cancer (2025 Edition)

IF 3.1 Q3 GERIATRICS & GERONTOLOGY

Aging Medicine Pub Date : 2026-03-17 Epub Date: 2026-03-11 DOI:10.1002/agm2.70067

National Center of Gerontology, Lung Cancer Committee of Beijing Oncology Association, Editorial Board of Chinese Journal of Geriatrics, Li Lin, Nie Xin, Wei Qian, Li Xu, Tian Yumeng, Wu Lin, Wang Jingyi, Wang Zhijie, Wang Mingzhao, Cao Baoshan, Gu Yangchun, Huang Meijuan, Yu Min, Yang Bo, Song Qi

{"title":"Chinese Expert Consensus on Immune Checkpoint Inhibitor Therapy for Elderly Patients with Advanced Non-small Cell Lung Cancer (2025 Edition)","authors":"National Center of Gerontology, Lung Cancer Committee of Beijing Oncology Association, Editorial Board of Chinese Journal of Geriatrics, Li Lin, Nie Xin, Wei Qian, Li Xu, Tian Yumeng, Wu Lin, Wang Jingyi, Wang Zhijie, Wang Mingzhao, Cao Baoshan, Gu Yangchun, Huang Meijuan, Yu Min, Yang Bo, Song Qi","doi":"10.1002/agm2.70067","DOIUrl":null,"url":null,"abstract":"<p>Immune checkpoint inhibitors (ICIs) are an important treatment option for patients with advanced non-small cell lung cancer (NSCLC). There remains significant uncertainty regarding immunotherapy regimen selection and safety management for elderly lung cancer patients, due to the insufficient inclusion of geriatric patients in current clinical studies and the absence of specific management guidelines or consensus statements for immunotherapy in the elderly population. The consensus integrates the latest evidence-based medical evidence worldwide with clinical practice experience in China. It provides recommendations on key challenges in immunotherapy for elderly patients with advanced NSCLC, including geriatric assessment, treatment regimen selection, management of adverse reactions, and future research directions, aiming to provide a reference for clinical practice.</p>","PeriodicalId":32862,"journal":{"name":"Aging Medicine","volume":"9 1","pages":"5-19"},"PeriodicalIF":3.1000,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agm2.70067","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/agm2.70067","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immune checkpoint inhibitors (ICIs) are an important treatment option for patients with advanced non-small cell lung cancer (NSCLC). There remains significant uncertainty regarding immunotherapy regimen selection and safety management for elderly lung cancer patients, due to the insufficient inclusion of geriatric patients in current clinical studies and the absence of specific management guidelines or consensus statements for immunotherapy in the elderly population. The consensus integrates the latest evidence-based medical evidence worldwide with clinical practice experience in China. It provides recommendations on key challenges in immunotherapy for elderly patients with advanced NSCLC, including geriatric assessment, treatment regimen selection, management of adverse reactions, and future research directions, aiming to provide a reference for clinical practice.

Abstract Image

查看原文本刊更多论文

免疫检查点抑制剂治疗老年晚期非小细胞肺癌中国专家共识（2025版）

免疫检查点抑制剂（ICIs）是晚期非小细胞肺癌（NSCLC）患者的重要治疗选择。老年肺癌患者的免疫治疗方案选择和安全管理仍然存在很大的不确定性，因为目前的临床研究没有充分纳入老年患者，并且缺乏针对老年人群免疫治疗的具体管理指南或共识声明。该共识将全球最新的循证医学证据与中国的临床实践经验相结合。就老年晚期NSCLC患者免疫治疗面临的关键挑战提出建议，包括老年评估、治疗方案选择、不良反应处理以及未来的研究方向，旨在为临床实践提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aging Medicine Medicine-Geriatrics and Gerontology

CiteScore

4.10

自引率

0.00%

发文量